PET-based prognostic survival model after radiotherapy for head and neck cancer.

Female Fluorodeoxyglucose F18 Head and Neck Neoplasms / diagnostic imaging Humans Male Middle Aged Positron Emission Tomography Computed Tomography Prognosis Proportional Hazards Models Retrospective Studies
Head and neck cancer Nomogram PET Prognostic score Radiotherapy

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
03 2019
Historique:
received: 06 07 2018
accepted: 13 08 2018
pubmed: 23 8 2018
medline: 14 6 2019
entrez: 23 8 2018
Statut: ppublish

Résumé

The aims of this multicentre retrospective study of locally advanced head and neck cancer (LAHNC) treated with definitive radiotherapy were to (1) identify positron emission tomography (PET)- A total of 237 consecutive LAHNC patients divided into training (n = 127) and validation cohorts (n = 110) were retrospectively analysed. The following PET parameters were analysed: SUV In univariate analysis, the significant PET parameters for the primary tumour included MTV (relative thresholds from 6 to 83% and absolute thresholds from 1.5 to 6.5) and TLG (relative thresholds from 1 to 82% and absolute thresholds from 0.5 to 4.5). For the lymph nodes, the significant parameters included MTV and TLG regardless of the threshold value. In multivariate analysis, tumour site, p16 status, MTV35% of the primary tumour, and MTV44% of the lymph nodes were independent predictors of OS. Based on these four parameters, a prognostic model was identified with a c-index of 0.72. The corresponding nomogram was generated. This prognostic model was externally validated, achieving a c-index of 0.66. A prognostic model of OS based on primary tumour and lymph node MTV, tumour site, and p16 status was proposed and validated. The corresponding nomogram may be used to tailor individualized treatment.

Identifiants

DOI: 10.1007/s00259-018-4134-9 PMID: 30132054
pubmed: 30132054
doi: 10.1007/s00259-018-4134-9
pii: 10.1007/s00259-018-4134-9
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

638-649

Subventions

Organisme : Swiss National Science Foundation
ID : PZ00P2_154891
Pays : Switzerland

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
BMC Med Res Methodol. 2013 Mar 06;13:33
pubmed: 23496923
Laryngoscope. 2014 Dec;124(12):2732-8
pubmed: 25042474
Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1297-305
pubmed: 22532254
J Nucl Med. 2013 Oct;54(10):1703-9
pubmed: 24042030
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138
pubmed: 29948105
Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):721-9
pubmed: 25752384
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1514-20
pubmed: 22270174
Ann Oncol. 2013 Jan;24(1):208-14
pubmed: 23002280
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9
pubmed: 9226314
Radiat Oncol. 2013 May 30;8:132
pubmed: 23721062
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Head Neck. 2016 Apr;38 Suppl 1:E600-6
pubmed: 25786981
Ann Nucl Med. 2012 Aug;26(7):527-34
pubmed: 22610386
PLoS One. 2015 Feb 18;10(2):e0117924
pubmed: 25692986
Clin Nucl Med. 2017 Jun;42(6):e281-e285
pubmed: 28288042
J Nucl Med. 2015 Feb;56(2):183-9
pubmed: 25613534
Lancet Oncol. 2012 Feb;13(2):145-53
pubmed: 22261362
Acta Oncol. 2015;54(9):1423-9
pubmed: 26264429
Cancer Med. 2014 Oct;3(5):1368-76
pubmed: 25045041
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):514-21
pubmed: 20646870
Head Neck. 2013 May;35(5):747-55
pubmed: 22267298
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Eur J Nucl Med Mol Imaging. 2014 May;41(5):915-24
pubmed: 24346414
Head Neck. 2002 Feb;24(2):127-35
pubmed: 11891942
Radiother Oncol. 2006 Aug;80(2):151-6
pubmed: 16920211
Eur J Cancer. 2017 Apr;75:222-230
pubmed: 28237868
Br J Cancer. 2015 Jan 20;112(2):251-9
pubmed: 25562432
J Med Imaging Radiat Oncol. 2017 Feb;61(1):99-123
pubmed: 27469298
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):419-28
pubmed: 25339524
Head Neck. 2013 Jan;35(1):15-22
pubmed: 22307893
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):412-422
pubmed: 29192365
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1449-58
pubmed: 21461734
Eur J Nucl Med Mol Imaging. 2017 May;44(5):801-811
pubmed: 28004135
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Crit Rev Oncol Hematol. 2016 Dec;108:40-51
pubmed: 27931839
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):659-67
pubmed: 24196922
AJR Am J Roentgenol. 2014 Oct;203(4):897-903
pubmed: 25247958
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1203-11
pubmed: 21350962
Eur Radiol. 2014 Sep;24(9):2077-87
pubmed: 24965509
Clin Exp Otorhinolaryngol. 2015 Jun;8(2):142-8
pubmed: 26045913
Br J Radiol. 2016 Nov;89(1067):20160217
pubmed: 27416996
Nucl Med Biol. 2015 Nov;42(11):899-904
pubmed: 26275933
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):429-37
pubmed: 25416633
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):617-25
pubmed: 26577940
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1984-94
pubmed: 26081941
Clin Nucl Med. 2015 Mar;40(3):e196-200
pubmed: 25608156
J Nucl Med. 2007 Jun;48(6):973-80
pubmed: 17536108
Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30
pubmed: 10701741
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Lancet. 2000 Mar 18;355(9208):949-55
pubmed: 10768432
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):630-7
pubmed: 12062606
Head Neck. 2015 Oct;37(10):1524-31
pubmed: 24890445

Auteurs

Joël Castelli (J)

Radiotherapy Department, Cancer Institute Eugène Marquis, 35000, Rennes, France. j.castelli@rennes.unicancer.fr.
INSERM, U1099, 35000, Rennes, France. j.castelli@rennes.unicancer.fr.
University of Rennes 1, LTSI, 35000, Rennes, France. j.castelli@rennes.unicancer.fr.
ORCID: 0000-0001-6128-1836

A Depeursinge (A)

Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, VD, Switzerland.
University of Applied Sciences Western Switzerland, 3960, Sierre, Switzerland.

A Devillers (A)

Nuclear Medicine Department, Cancer Institute Eugène Marquis, 35000, Rennes, France.

B Campillo-Gimenez (B)

INSERM, U1099, 35000, Rennes, France.
University of Rennes 1, LTSI, 35000, Rennes, France.
Clinical Research Direction, Cancer Institute Eugène Marquis, 35000, Rennes, France.

Y Dicente (Y)

Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, VD, Switzerland.
University of Geneva, 1211, Geneva, Switzerland.

J O Prior (JO)

Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.

E Chajon (E)

Radiotherapy Department, Cancer Institute Eugène Marquis, 35000, Rennes, France.

F Jegoux (F)

Head and Neck Department, CHU Rennes, F-35000, Rennes, France.

C Sire (C)

Radiotherapy Department, Lorient Hospital, F-56100, Lorient, France.

O Acosta (O)

INSERM, U1099, 35000, Rennes, France.
University of Rennes 1, LTSI, 35000, Rennes, France.

E Gherga (E)

Radiotherapy Department, CHU Besançon, Besançon, France.

X Sun (X)

Radiotherapy Department, CHU Besançon, Besançon, France.
Radiotherapy Department, Hôpital Nord Franche Comté Montbéliard, Montbéliard, France.

B De Bari (B)

Radiotherapy Department, Hôpital Nord Franche Comté Montbéliard, Montbéliard, France.

J Bourhis (J)

Radiotherapy Department, Lausanne University Hospital, Lausanne, Switzerland.

R de Crevoisier (R)

Radiotherapy Department, Cancer Institute Eugène Marquis, 35000, Rennes, France.
INSERM, U1099, 35000, Rennes, France.
University of Rennes 1, LTSI, 35000, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › PET-based prognostic survival model after...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › PET-based prognostic survival model after...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PET-based prognostic survival model after...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › PET-based prognostic survival model after...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › PET-based prognostic survival model after...
questionsmedicales.fr › Diagnostic › Pronostic › PET-based prognostic survival model after...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › PET-based prognostic survival model after...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › PET-based prognostic survival model after...